2MBCD Antibody

2MBCD Deficiency Overview

2MBCD deficiency is caused by mutations in the ACADSB gene, leading to impaired isoleucine metabolism. Symptoms include metabolic acidosis, hypoglycemia, and acute crises, though many individuals remain asymptomatic . The enzyme 2MBCD facilitates the breakdown of 2-methylbutyryl-CoA, an intermediate in isoleucine catabolism.

Antibody Engineering in Metabolic Disorders

While no specific antibody for 2MBCD is described in the sources, therapeutic antibodies targeting metabolic enzymes are an active research area. For example:

• DuoMab, a bivalent antibody format, enhances Fc-mediated effector functions (e.g., ADCC) through increased Fc load on target cells . Such designs could theoretically be adapted to modulate enzyme activity or clearance in metabolic disorders.

• Exome sequencing has improved diagnostic accuracy for inborn errors like 2MBCD deficiency, reducing reliance on antibody-based assays .

Diagnostic Tools for 2MBCD Deficiency

Current diagnostics focus on metabolite profiling (e.g., tandem mass spectrometry) and genetic testing. Antibodies in this context are primarily used for enzyme-linked immunosorbent assays (ELISAs) to detect enzyme levels or activity. For example:

• Anti-IVD antibodies (targeting isovaleryl-CoA dehydrogenase) have been studied for diagnostic purposes in isovaleric acidemia , a related condition.

Research Gaps and Future Directions

Clinical and Diagnostic Considerations

• Newborn screening programs increasingly use exome sequencing to identify 2MBCD deficiency, bypassing antibody-based methods .

• Therapeutic antibodies for metabolic enzymes remain experimental, with challenges including antigen specificity and immunogenicity.